Effects of heat treatment on magnetic properties of Co–Fe-plated hollow ceramic microspheres

Functional hollow ceramic microspheres plated with Co-Fe were obtained through electroless plating technique for the application of lightweight microwave absorbers.They were treated at different temperatures by vacuum annealing method.The surface-coated hollow microspheres were characterized by scanning electron microscopy(SEM) and X-ray diffraction analysis (XRD).The microwave electromagnetic loss and absorbing properties of hollow microspheres plated with Co-Fe were tested by network vector analysis.Th...     

超临界法制备多孔纳米Fe3O4/SiO2复合磁性微球及性能

为了制备具有纳米多孔结构的磁性复合微球,采用正硅酸四乙酯(TEOS)和金属氯盐分别作为SiO2和铁氧体的前驱体,通过溶胶凝胶法制备将Fe3O4纳米颗粒分散于SiO2基体中的Fe3O4/SiO2磁性纳米复合微球,并用超临界干燥法对其进行干燥。利用X线衍射(XRD)、红外光谱(IR)、透射电镜(TEM)和振动试样磁场计(VSM)等分析测试手段对合成的材料进行性能表征。结果表明:复合粒子包覆完好、性能优良、分散性良好,制备颗粒的粒径为30 nm,比饱和磁化强度为84.09 A.m2/kg。     

浓乳液聚合法制备聚(苯乙烯-二乙烯基苯)微球的研究

以苯乙烯、二乙烯基苯为单体,采用浓乳液聚合的方法制备得到聚(苯乙烯-二乙烯基苯)微球.通过热失重分析仪研究了聚(苯乙烯-二乙烯基苯)微球的热降解性能,并研究了单体配比、乳化剂用量等对该微球粒径及形态的影响.结果表明:乳化剂用量越多,聚(苯乙烯-二乙烯基苯)微球粒径越小;二乙烯基苯用量越多,微球粒径也越小.     

一种新型金属螯合亲和色谱固定相的制备及评价

采用溶胶-凝胶法,在正庚烷乳液中生成1.5μm的无孔脲醛树脂-二氧化锆复合微球基体,其与丙烯酸甲酯进行迈克尔加成反应后,通过亲核取代反应与螯合剂亚氨基二乙酸(IDA)键合,制成IDA-UF-ZrO2固定相,此固定相与铜离子(Ⅱ)螯合后,形成金属螯合亲和色谱固定相(Cu-IDA-UF-ZrO2).以牛血清白蛋白(BSA)为样品,考察了两种新合成的固定相的色谱性能,结果表明BSA在Cu-IDA-UF-ZrO2上的保留时间比在IDA-UF-ZrO2上的保留时间有所增加,同时BSA在Cu-IDA-UF-ZrO2上的保留主要受固定金属离子与蛋白质侧链上氨基酸间配位作用的影响.     

多孔钛植入体表层孔隙内TGF-β1缓释明胶微球涂层的工艺优化

采用正交试验法优化载转化生长因子β1(transforming growth factor-β1,TGF-β1)缓释明胶微球多孔钛植入体制备工艺,探讨多孔钛植入体孔隙内微球涂层的载药、释药特性.采用粉末注射成形(Metal Injection Molding, MIM)技术制备多孔钛植入体,选用明胶为TGF-β1缓释载体材料,乳化冷凝聚合交联法制备明胶微球,检测微球粒径与形貌以及载TGF-β1微球的包封率、载药率,采用渗涂法制备多孔钛表层孔隙内载TGF-β1明胶微球涂层,释放试验检测涂层的释药特性.实验结果表明,MIM技术制备的多孔钛植入体的孔隙度为(62.02±1.82)%,孔径为50～300 μm,抗压缩强度为(63.23±12.81) MPa,弹性模量为(0.95±0.61) GPa.明胶微球粒径随明胶浓度的减小、搅拌速度和交联时间的增加而减小,交联剂用量对微球粒径影响无显著性差异.制备的TGF-β1明胶微球为球形,平均粒径为(21.42±3.67) μm,载药量为(0.91±0.02) μg/g,包封率为(91.41±1.82)%.TGF-β1微球涂层体外14 d,时的TGF-β1释放率为(94.2±3.4)%;粒径为(21.42±3.67) μm的明胶微球的最佳工艺参数如下:明胶浓度为10%,搅拌速度为800 r/min,交联剂用量为0.1 mL,交联时间为2 h.多孔钛植入经5%(质量分数)明胶溶液预处理后用20 g/L微球渗涂可在表层孔隙内形成均匀微球涂层,且不阻塞表层孔隙,微球涂层TGF-β1释放时间为14 d.     

喷雾法制备载牛血清白蛋白海藻酸钙微球系统研究

采用喷雾法制备了载牛血清白蛋白(BSA)的海藻酸钙微球,通过比较微球的平均粒径和包埋率,优化了喷雾法的制备参数,使微球对BSA的包埋率大于60%、载药率达8%以上.释放液中BSA的SDS-聚丙烯酰胺凝胶电泳、Western免疫印迹以及圆二色光谱显示,该制备方法并没有对被包埋蛋白的相对分子质量、抗原性以及二级结构产生影响.微球中BSA的体外释放曲线表明该给药系统具有pH响应特性,尤其在模拟胃液中,BSA的释放速率最慢、释放量最低,可以保护蛋白类药物免受胃酸等的破坏作用,达到肠部实现控制释放.     

介绍一个与材料科学有关的综合化学实验

介绍了一个与材料科学有关的综合化学实验—多级CdSe微米球的水热合成、表征及光学性能。实验涵盖材料化学、无机合成和仪器分析等方面,可以使学生了解微/纳米材料的基本知识,掌握水热法合成微/纳米材料的原理和方法,并了解分析微/纳米材料物质结构、形貌和光学性能的基本方法,有利于培养学生的实践能力和创新能力。     

盐酸二甲双胍pH敏感性水凝胶微球的制备

为减轻盐酸二甲双胍对胃的刺激,实现其在肠道内的释放,以盐酸二甲双胍为主药,壳聚糖、海藻酸钠为复合载体,筛选盐酸二甲双胍pH敏感性水凝胶微球的最佳处方及制备工艺,并对其pH敏感性及体外释药特性进行了考察。通过单因素试验及正交试验优化处方工艺,利用扫描电镜进行结构表征,紫外分光光度法测定载药量及包封率,转篮法研究释放度。结果表明,盐酸二甲双胍pH敏感性水凝胶微球的优选处方如下:壳聚糖与海藻酸钠的总浓度为2%(质量体积比),海藻酸钠与壳聚糖的质量比为1∶1,药物与海藻酸钠的质量比为2∶5,氯化钙的交联浓度为3.5%(质量体积比);盐酸二甲双胍pH敏感性水凝胶微球在人工胃液中6 h累积释放度小于4%,在人工肠液中6 h累积释放度最大可达96.4%。所制备的盐酸二甲双胍pH敏感性水凝胶微球处方工艺稳定可靠,水凝胶微球机械强度高,生物降解性和稳定性好,是一种新型结构的盐酸二甲双胍给药系统。     

基于酸碱溶胀法制备微米级中空聚合物微球的研究

通过种子乳液聚合法制备得到亲水核与核壳结构微球,采用酸碱溶胀法处理核壳微球,制备了微米级中空微球。扫描电子显微镜、透射电子显微镜等测试分析表明,单分散性的亲水核平均直径约465 nm;单分散的核壳微球表面略显粗糙,平均直径约560 nm,疏水壳层厚度约100 nm;微米级中空微球的直径约1.20μm,中空度为21.6%,其单分散性与球形度良好。在亲水核聚合过程中,当m(MMA)/m(MAA)=1.771时,乳液反应体系稳定,得到亲水核微球的单分散性最好。     

A novel injectable fibroblasts-porous PDLLA microspheres/collagen gel composite for soft-tissue augmentation

This study designed a novel porous PDLLA microspheres/collagen gel composite combined with fibroblasts as the injectable dermal filler for soft-tissue augmentation. The low degradation rate of porous PDLLA microspheres and seed cells were introduced in the system to achieve the filling volume stability and stronger regeneration activity. Biodegradable PDLLA porous microspheres were prepared by an improved water-in-oil-in-water double emulsion solvent evaporation method. The combine of fibroblasts with porous microspheres was observed through co-culture of cells with microspheres, SEM (scanning electron microscope) and fluorescent staining technology. The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay, the hemolysis test and histocompatibility experiment indicated that the composite had satisfactory biocompatibility in vitro and in vivo. In the animal studies, the composite was implanted into the subcutaneous part of the rats’ back through sterile needles. The collagen was metabolized within 30 days, meanwhile, fibroblasts-porous PDLLA microspheres served as scaffold structure and seed cells which promote new connective tissue formation. The histopathological studies demonstrate that the fibroblasts-porous PDLLA microspheres/collagen gel composite group could create larger amount of supportive structure than PDLLA porous microspheres/collagen gel composite group. All the results indicate that fibroblasts-porous PDLLA microspheres/collagen gel composite may have great clinical application in soft-tissue augmentation with its excellent biocompatibility, regeneration activity and stable long-term filling ability.